Protein Trend Competition Threatens Infant Formula Supply as Whey Protein Demand Spikes

The Quick Take

• Surging whey protein demand from proteinmaxxing fitness trend may raise infant formula ingredient costs
• GLP-1 drug adoption is also driving whey demand as users prioritize muscle preservation during weight loss
• Reckitt, Danone, and Abbott face potential raw material cost pressures as shared supply competes for allocation

Synthesized from 1 source including The Guardian Business (tier 1)

The rise of proteinmaxxing -- a consumer wellness trend in which individuals maximize daily protein intake across all meals and snacks -- is creating unexpected pressure on whey protein supply chains that also supply the infant formula manufacturing industry. The Guardian's reporting cites expert concerns that rising whey protein demand from fitness and wellness consumers is competing with the infant formula sector for the same dairy byproduct, with potential upstream cost consequences for formula manufacturers. The trend has accelerated over the past year as health professionals have amplified protein consumption messaging, and social media wellness communities have made high-protein dietary frameworks mainstream beyond traditional athletic demographics.

A secondary demand driver is compounding the supply tension: GLP-1 weight-loss drug users are being advised by clinicians to prioritize protein consumption to preserve lean muscle mass during the accelerated weight loss that Ozempic and Mounjaro produce. As GLP-1 prescription volumes continue to grow -- now measured in millions of active users across the US and UK -- the dietary protein emphasis among this cohort adds structurally elevated whey protein demand on top of the proteinmaxxing trend. Infant formula manufacturers including Reckitt Benckiser, Danone, and Abbott Laboratories source whey protein as a key nutritional ingredient, and any sustained supply tightness would translate into raw material cost inflation that could pressure margins or consumer prices.

The investment implications are nuanced. Dairy processors and whey protein ingredient suppliers -- particularly European dairy cooperatives like FrieslandCampina and Arla Foods -- stand to benefit from improved pricing power if demand structurally outpaces whey protein supply from cheese manufacturing byproduct volumes. Infant formula companies face an indirect margin headwind, but their pricing power in the regulated infant nutrition market varies significantly by geography. In the UK and EU, where formula prices are more tightly supervised and competition from own-label brands is limited, cost inflation may be absorbed more readily by manufacturers. Investors monitoring Reckitt (LSE: RKT), Danone (ENXTPA: BN), and Abbott (NYSE: ABT) should assess ingredient cost sensitivity in forward earnings guidance.